Evidence map›Paper›PMID 32444945›Full record

ReviewJournal of cardiovascular translational research2020

Clinical Practice and Research in Cardio-Oncology: Finding the "Rosetta Stone" for Establishing Program Excellence in Cardio-oncology.

Srinath Adusumalli, Jose Alvarez-Cardona, Sameed M Khatana, Joshua D Mitchell, Anne H Blaes, Stephen J Casselli, Rupal O'Quinn, Daniel J Lenihan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cardiovascular translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Cardiology and oncology: a meeting of giants.Revista da Associacao Medica Brasileira (1992) · 2024
    Article
  2. Cardio-Oncology Care Delivered in the Non-academic Environment.Current treatment options in oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Srinath AdusumalliDepartment of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jose Alvarez-CardonaCardio-Oncology Center of Excellence, Division of Cardiovascular Medicine, Washington University in St Louis, 660 South Euclid Avenue, Campus box 8086, St. Louis, MO, 63110-1093, USA.
Sameed M KhatanaDepartment of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Joshua D MitchellCardio-Oncology Center of Excellence, Division of Cardiovascular Medicine, Washington University in St Louis, 660 South Euclid Avenue, Campus box 8086, St. Louis, MO, 63110-1093, USA.
Anne H BlaesDepartment of Medicine, Division of Hematology/Oncology, University of Minnesota, Minneapolis, MN, USA.
Stephen J CasselliThe International Cardio-Oncology Society, Tampa, FL, USA.
Rupal O'QuinnDepartment of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Daniel J LenihanCardio-Oncology Center of Excellence, Division of Cardiovascular Medicine, Washington University in St Louis, 660 South Euclid Avenue, Campus box 8086, St. Louis, MO, 63110-1093, USA. djlenihan@wustl.edu.
University of Pennsylvania · USWashington University in St. Louis · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The burgeoning field of cardio-oncology (C-O) is now necessary for the delivery of excellent care for patients with cancer. Many factors have contributed to this increasing population of cancer survivors or those being treated with novel and targeted cancer therapies. There is a tremendous need to provide outstanding cardiovascular (CV) care for these patients; however, current medical literature actually provides a paucity of guidance. C-O therefore provides a novel opportunity for clinical, translational, and basic research to advance patient care. This review aims to be a primer for cardio-oncologists on how to develop a vibrant and comprehensive C-O program, use practical tools to assist in the construction of C-O services, and to proactively incorporate translational and clinical research into the training of future leaders as well as enhance clinical care.

Indexed as

Cancer SurvivorsAntineoplastic AgentsCardiac Imaging TechniquesCardiologyCardiotoxicityComprehensive Health CareDelivery of Health Care, IntegratedHeart DiseasesHumansMedical OncologyNeoplasmsPredictive Value of TestsPrognosisQuality Indicators, Health CareRisk AssessmentRisk FactorsAntineoplastic AgentsCardio-oncologyPractice excellenceProgram developmentTranslational research

Identifiers

PMID32444945
OpenAlexW3027990316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.